OpenEvidence vs Abridge
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
|
|
Abridge
Ambient AI scribe for clinicians — 200+ health systems, Best in KLAS
Visit
|
|
|---|---|---|
| RECATOOLS Score | 7.8 / 10 | 8.2 / 10 |
| Capability | ||
| Value for money | ||
| Ease of use | ||
| ASEAN readiness | ||
| API quality | ||
| Pricing | Freemium | Enterprise |
| Free tier | Free for all verified US clinicians (NPI required); ad-supported | None — enterprise contracts only, no self-serve or trial tier |
| Paid from | Enterprise tier in development; pricing undisclosed — contact sales | Enterprise quote only; no public self-serve pricing (12-month minimum) |
| Has API | ✗ | ✗ |
| Open source | ✗ | ✗ |
| Free to use | ✓ | ✗ |
| Users | ~860,000 verified US clinicians (June 2026) | 200+ health systems; ~50-80M clinical conversations/year |
| Founded | 2022 | 2018 |
| Maker | Daniel Nadler (CEO), Zachary Ziegler (CTO) | Abridge AI, Inc. (independent) |
| Verdict | OpenEvidence is genuinely useful for US clinicians: free, citation-backed answers pulled from NEJM, JAMA, and AMA guidelines, funded by pharma advertising instead of subscriptions. Growth has been extraordinary — over 69... |
Abridge is the clear market leader in ambient AI documentation for large US health systems, validated by more peer-reviewed research than any competitor, Best in KLAS two consecutive years, and deployments at the most pr... |
| Full review → | Full review → |
← Back to AI Directory
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.